Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.65 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070553 | 0.91 | CYP4F2 (0.76) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL4425984 | 0.91 | CYP4F2 (0.64) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL10725552 | 0.88 | CYP4F2 (0.61) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL3168505 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL13104077 | 0.86 | CYP4F2 (0.58) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL3175580 | 0.84 | CYP4F2 (0.57) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL3159659 | 0.84 | PPARA (0.60) | CYP4F2CYP4A11PPARAPPARGTDP1 | |
| SCHEMBL19089798 | 0.84 | CYP4F2 (0.61) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL10504954 | 0.83 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL2174850 | 0.83 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARAPPARGALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102442941-A | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-101636386-A | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2010-01-27 | — | — | CN | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008072784-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | CYP4F2 4600/4885CYP4A11 3026/4885PPARA 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.